Stem cell drug company Osiris Therapeutics Inc (NasdaqGM:OSIR) said on Friday that it has ended its collaboration with Genzyme, upon which all rights to Prochymal and Chondrogen worldwide revert back to Osiris.
Upon closing, Osiris is now free to commercialise or enter into commercialisation agreements for Prochymal and Chondrogen with other parties without limitation.
is about to undergo a mid-to-late-stage trial for arthritis of the knee.
OA patients receiving Chondrogen experienced a statistically significant reduction in pain compared to those receiving the control, HA.
5 times more likely to experience degenerative bone changes associated with OA as compared to those receiving Chondrogen.
The effects were dose dependent and pain scores improved from six months to one year following treatment, suggesting Chondrogen caused a biological modification of OA.
Most recently, Osiris won approval from the US Food and Drug Administration (FDA) to begin a Phase I/II study for its third product, Chondrogen
, an injection of stem cells formulated to repair damaged tissue in the knee joint and prevent the progression of arthritis.
Osiris is now free to commercialize or enter into commercialization agreements for Prochymal and Chondrogen
with other parties without limitation.